BIO-key International
BKYI
0 hedge funds and large institutions have $0 invested in BIO-key International in 2026 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 10 closing their positions.
0.39% less ownership
Funds ownership: 0.39% → 0% (-0.39%)
100% less funds holding
Funds holding: 10 → 0 (-10)
100% less capital invested
Capital invested by funds: $227K → $0 (-$227K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 10
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$157K |
| 2 |
Citigroup
New York
|
-$26.7K |
| 3 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
-$18.5K |
| 4 |
VF
Virtu Financial
New York
|
-$11K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$9.11K |
BKYI Hedge Fund Activity: Q2 2026 in Review
0 institutional investors reported a position in BIO-key International (BKYI) for Q2 2026, worth a combined $0 — down 100% from $227K a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of BKYI and 0 opened new positions — a net loss of 10 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Geode Capital Management, exiting entirely with an estimated $157K sold.
- 0 institutional investors held BIO-key International (BKYI) as of Q2 2026, down from 10 in Q1 2026.
- Funds reported $0 of BIO-key International stock for Q2 2026, down 100% quarter-over-quarter.
- 0 funds opened new BIO-key International positions in Q2 2026 and 10 closed out, a net change of -10 holders.
- The largest BIO-key International seller in Q2 2026 was Geode Capital Management, an estimated $157K sold.
Based on aggregated 13F filings for Q2 2026.